[video+transcript] How Big Could Amarin's Vascepa Be?

[video+transcript] How Big Could Amarin's Vascepa Be?

Source: 
Motley Fool
News Tags: 
snippet: 

Amarin (NASDAQ:AMRN) recently reported data from a long-running study of its fish oil pill, Vascepa, that could reshape how cardiologists treat their patients.

In today's clip from The Motley Fool's Industry Focus: Healthcare, host Shannon Jones and Motley Fool contributor Todd Campbell discuss how Vascepa can reduce the risk of major cardiovascular events, and why the study's results may turn Vascepa into a billion-dollar blockbuster.